Browse the evidence

The dual stimulation of the GIP and GLP1 receptor may provide benefits in treating type 2 diabetes and obesity.

Consider dual receptor agonists in treatment plans for better outcomes in diabetes and obesity.

GLP-1 receptor (GLP-1R) agonists significantly reduce the occurrence of major adverse cardiovascular events in individuals with type 2 diabetes (T2D).

Practitioners should consider GLP-1R agonists as a therapeutic option for reducing cardiovascular risks in T2D patients.

Incretin-based glucose-lowering medications, including DPP-4 inhibitors and GLP-1 receptor agonists, open new perspectives in the treatment of type 2 diabetes.

Practitioners should consider incretin-based therapies as viable options for managing type 2 diabetes.

The dual receptor agonist tirzepatide has been approved for clinical use by the FDA.

Healthcare providers can now prescribe tirzepatide as part of diabetes management.

Glucagon-like peptide 1 receptor agonists hold great promise to reverse some cancer risk in people living with obesity.

GLP-1 receptor agonists may be considered in obesity management to potentially reduce cancer risk.

Liraglutide reduced global eating disorder risk scores.

Practitioners may consider liraglutide as a treatment option for reducing eating disorder risk in patients with obesity or Type 2 diabetes.

Food cravings improved or remained unchanged following liraglutide and semaglutide treatment.

Practitioners should be aware that while some patients may experience reduced cravings, others may not see changes.

PAP+semaglutide was associated with lower incident pulmonary hypertension (PH) at 1 year (RR:0.45) and at 3 years (RR:0.50), and lower mortality at 1 year (RR:0.35) and 3 years (RR:0.37).

Incorporating GLP-1 receptor agonists like semaglutide may enhance treatment outcomes for obese patients with OSA on PAP.

The increase in body protein mass due to the energy surplus was correlated with an increase in fat mass (r = 0.820, p = 0.002).

Increased body fat may play a role in promoting body protein mass gain.

Glucagon-like peptide 1 receptor agonists consistently reduce three-point major adverse cardiovascular events (MACE) in patients with overweight, obesity, and established cardiovascular disease (CVD) with and without diabetes.

Practitioners can consider glucagon-like peptide 1 receptor agonists as effective treatments for reducing cardiovascular events in eligible patients.

Semaglutide and tirzepatide improve symptoms and functional capacity in obesity-related heart failure of preserved ejection fraction and reduce worsening heart failure events.

Practitioners can use semaglutide and tirzepatide to improve heart failure symptoms in patients with obesity.

For the low-fat diet, income, leptin, education, low-density lipoprotein, and dietary adherence at baseline are significant predictors of weight loss success.

Practitioners should assess these factors when advising on low-fat diets.

A pilot RCT is being conducted to compare the effects of low-fat vs. low-glycemic load diets on bioavailable testosterone in girls with PCOS.

Practitioners may consider dietary interventions as a first-line non-pharmacologic treatment for PCOS.

Tirzepatid is being studied for its safety and efficacy as a treatment for obesity.

Practitioners should consider Tirzepatid as a potential treatment option for obesity.

Tirzepatid is being studied for its safety and efficacy as a treatment for obesity.

Practitioners should consider Tirzepatid as a potential treatment option for patients with obesity.

Obesity has a compelling influence on fertility and reproductive health.

Healthcare practitioners should consider the impact of obesity on reproductive health when treating patients.

Obesity in females is correlated with menstrual abnormalities, infertility, and complications during gestation.

Clinicians should assess reproductive health in obese female patients.

Tirzepatide has been approved by the FDA for type 2 diabetes in adults as a single dose weekly.

Practitioners can prescribe Tirzepatide for managing type 2 diabetes in adults.

Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity.

Practitioners should be aware of Tirzepatide's potential for treating obesity in clinical settings.

There is increasing acceptance of anti-obesity medications as an adjunct to lifestyle modifications and/or surgery.

Practitioners should consider integrating pharmacotherapy with lifestyle changes and surgical options for comprehensive obesity management.

GLP-1 agonists improve blood glucose profiles and reduce cardiovascular risk.

GLP-1 agonists can be recommended for improving glycemic control and reducing cardiovascular risks in diabetic patients.

Dual GIP/GLP-1 agonists are more effective in treating obesity than GLP-1 agonists alone.

Consider dual GIP/GLP-1 agonists for potentially better outcomes in obesity treatment.

Patients treated with semaglutide experienced a greater improvement in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) compared to placebo, with an estimated treatment difference of 7.8 points (P < .001).

Semaglutide may be an effective treatment option for improving heart failure symptoms in obese patients.

Co-stimulation of GLP-1 with other receptors provides additional therapeutic benefits.

Combining GLP-1 therapy with other hormonal treatments may enhance effectiveness.